Meet the Mass General Brigham Ventures Team

Our team combines proven investment acumen with the scientific background necessary to analyze the risks and complexities of early-stage healthcare investing.

Our expertise encompasses venture financing, biomedical research, entrepreneurship, operational management, product development, and strategic partnering. The team works closely with Mass General Brigham’s extensive network of clinical and scientific experts to source opportunities and validate them as commercially viable concepts.  

Investment team

Roger Kitterman

Managing Partner
Carl Berke, PhD

Partner
Meredith Fisher, PhD

Partner
Julius Knowles

Partner
Stacey Brenner

Senior Director, Investor Relations and Finance
Bhamini Vaidialingam

Venture Associate

Entrepreneurs in residence

We partner with experienced entrepreneurs and scientists to build companies around innovative science. Our network of current and former entrepreneurs in residence complement and enhance our partnerships with scientific founders.

Stan Nowak

Digital Health Executive
Pauline Jen Ryan

Biotech Executive

Alumni entrepreneurs in residence

David de Graaf

Mediar Therapeutics, Board of Directors
Barbara Fox

Tilos Therapeutics, Founding CEO
(Acquired by Merck)
Robert Millman

Ncontrol Therapeutics, Founding CEO
CoStim, Co-Founder, President
(Acquired by Novartis)
John Ripple

Brave Bio, Board of Directors
Ellen Sheets, MD

SeQure DX, Founding CEO
Bill Yelle

FireCyte Therapeutics, Founding CEO

Commitment to diversity, equity and inclusion

At Mass General Brigham Ventures, diversity, equity and inclusion are central to every aspect of our organization. When our workforce is more equitable and inclusive, we can be more innovative, creative, and on the cutting edge of advancement. Leveraging diverse perspectives allows us to develop better overall solutions to the problems we face.

Learn more about diversity, equity and inclusion at Mass General Brigham